ArticleRedox biology2017
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Open access · goldAbstract read
In one paragraph
Article in Redox biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 2 pooled it
15.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 2 syntheses or guidelines pooled it, 297 citations in OpenAlex.
- Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.Endocrine · 2024Pooled it
- Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study.Cardiovascular diabetology · 2024Pooled it
- Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.Cardiovascular diabetology · 2025Trial
- Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.Cardiovascular diabetology · 2021 · on this mapTrial
- Antidiabetic medications and arterial thrombotic risk reduction: a narrative review.Internal and emergency medicine · 2026Review
- Impact of Complicated Diabetes Mellitus in Patients Following Severe Traumatic Brain Injury.Neurocritical care · 2026Article
- Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion.Basic research in cardiology · 2026Article
- The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease.Digestive diseases and sciences · 2026Review
- Empagliflozin and platelet-rich plasma improve stanozolol induced cardiotoxicity by reducing NF-κB/P65, IL-1B and apoptosis.BMC pharmacology & toxicology · 2026Article
- The SGLT2i "canagliflozin" and the DPP-4i "sitagliptin" mitigate hypertensive nephropathy in adult male rats by modulating the Ang II/RAGE/Nox4/NLRP3 cascade.Frontiers in physiology · 2026Article
- The Apelinergic System in Kidney Disease: Novel Perspectives.International journal of molecular sciences · 2025Review
- Effect of empagliflozin on human primary cardiomyocytes in a chemically induced hypoxia by CoClPhysiological reports · 2025Article
- The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025Review
- Effects of SGLT2 inhibitors on angiography-derived coronary microcirculatory resistance and clinical outcomes in patients with coronary heart disease and type 2 diabetes: A cohort study.Diabetology & metabolic syndrome · 2025Article
- GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies.Journal of clinical medicine · 2025Review
- Article
- Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.Pharmacological reviews · 2025Review
- Potential Role of SGLT-2 Inhibitors in Improving Allograft Function and Reducing Rejection in Kidney Transplantation.Clinical transplantation · 2025Review
- Empagliflozin Protects Against Oxidative Stress in the Diabetic Brain by Inducing HPharmaceuticals (Basel, Switzerland) · 2025Article
- Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors.Journal of the American Heart Association · 2025Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 2 countries.
Sebastian StevenCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Center for Thrombosis and Hemostasis, Medical Center of the Johannes Gutenberg University, Mainz, Germany, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Matthias OelzeCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Alina HanfCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Swenja Kröller-SchönCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Fatemeh KashaniCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Siyer RoohaniCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Philipp WelschofCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Maximilian KoppCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Ute Gödtel-ArmbrustDepartment of Pharmacology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Ning XiaInstitute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Huige LiInstitute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Eberhard SchulzCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Karl J LacknerInstitute for Advanced Biosciences, INSERM U1209 - CNRS UMR 5309, Grenoble-Alps University and Institute for Biology and Pathology, CHU, Grenoble, France.
Leszek WojnowskiDepartment of Pharmacology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Serge P BottariGerman Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.
Philip WenzelCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Center for Thrombosis and Hemostasis, Medical Center of the Johannes Gutenberg University, Mainz, Germany, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Eric MayouxBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Thomas MünzelCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Andreas DaiberCenter for Cardiology, Cardiology I - Laboratory of Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Electronic address: andreas.daiber@bioredox.com.
Johannes Gutenberg University Mainz · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEBoehringer Ingelheim (Germany) · DEGerman Centre for Cardiovascular Research · DEUniversité Grenoble Alpes · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance
Indexed as
Sodium-Glucose Transporter 2 InhibitorsAnimalsAorta, ThoracicBenzhydryl CompoundsC-Reactive ProteinDiabetic CardiomyopathiesEndothelium, VascularGlucoseGlucosidesGlycated HemoglobinHypoglycemic AgentsInsulin-Secreting CellsMaleOxidative StressRatsRats, ZuckerBenzhydryl CompoundsC-Reactive ProteinempagliflozinGlucoseGlucosidesGlycated HemoglobinHypoglycemic AgentsSlc5a2 protein, ratSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsAGE/RAGE signalingDiabetesEndothelial dysfunctionLow-grade inflammationOxidative stressSGLT2 inhibitorZucker diabetic fatty ratsβ-cell content
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.